TABLE 2.
Clinical and biological data from patients with other IFD, possible IFD, or no IFD and positive BAL fluid MucPCR result
| Patient no. | Age (yr) | Sexa | Underlying diseaseb | EORTC classificationc | Radiological sign(s) | Histology day, direct exam result, culture result (organism) | BAL fluid mycology day, direct exam result, culture (organism) | Galactomannan serum/BAL fluid result (D−7 to D+7) | BAL fluid MucPCR result, day (Cq) | Serum MucPCR result, day (Cq) | Liposomal amphotericin B day of initiationd | Outcome at D90 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11 | 60 | F | NHL, HSCT | Probable aspergillosis | Nodules | Not done | D0, Neg, Neg | Pos (BAL fluid 0.64) | Neg, D–5 (>45), Rhizomucor, D0 (34) | Neg, D0 (>45) | D4 (voriconazole before) | Death at D10 |
| 12 | 73 | M | AML | Probable aspergillosis | Cerebral abscess | Not done | D0, Neg, Neg | Pos (serum 0.95, BAL fluid 4.95) | Rhizomucor, D0 (35) | Rhizomucor, D0 (33) | D3 | Death at D26 |
| 13 | 43 | M | Aplasia | Probable aspergillosis | Nodules, ground-glass opacity | Not done | D−35, Neg, Pos (Aspergillus fumigatus) | Neg | Mucor/Rhizopus, D0 (39) | Neg, D6 (>45) | D0 (voriconazole before/improvement with L-AMB + posaconazole at D16) | Alive |
| 14 | 63 | F | AML | Probable aspergillosis | Condensation | Not done | D0, Pos, Pos (Aspergillus fumigatus) | Neg | Mucor/Rhizopus, D0 (28); Rhizomucor, D0 (34) | Neg, D–2 (>45), Rhizomucor, D5 (39); Mucor/Rhizopus D10 (37), D12 (38), D16 (37) | D5 (voriconazole before/improvement with L-AMB + isavuconazole at D9) | Alive |
| 15 | 28 | M | ALL, HSCT | Proven fusariosis | Halo sign, condensation, ground-glass opacity | Skin D8, Pos, Fusarium spp. | D0, Neg, Neg | Neg | Rhizomucor, D0 (33) | Rhizomucor, D0 (39) | D8 | Death at D51 |
| 16 | 64 | M | IM, HSCT | Possible IFD | Condensation | Not done | D0, Neg, Neg | Neg | Rhizomucor, D0 (40) | Rhizomucor, D0 (31) | D0 | Death at D12 |
| 17 | 58 | F | Liver transplant, diabetes | Possible IFD | Condensation | Not done | D0, Neg, Neg | Neg | Mucor/Rhizopus, D0 (33) | Neg, D5 (>45) | D3 | Alive |
| 18 | 61 | M | AML | Possible IFD | Nodules | Bronchial, D9, Neg, Neg | D0, Neg, Neg | Neg | Mucor/Rhizopus, D0 (30) | Mucor/Rhizopus, D−6 (38), D−2 (38), D2 (35) | D2 | Alive |
| 19 | 25 | M | MDS, HSCT | Possible IFD | Nodules, halo sign | Not done | D−15, Neg, Neg | Neg | Mucor/Rhizopus, D0 (36) | Mucor/Rhizopus, D0 (41) | D−20 | Death at D80 |
| 20 | 60 | M | AML | Possible IFD | Nodules | Not done | D0, Neg, Pos (Candida albicans) | Neg | Mucor/Rhizopus, D0 (27) | Neg, D–5 (>45), Mucor/Rhizopus, D−1 (36), D0 (35), D1 (37), D7 (34) | D7 + posaconazole | Death at D10 |
| 21 | 46 | F | CML | Possible IFD | Pleural effusion | Not done | D0, Neg, Neg | Neg | Rhizomucor, D0 (39) | Rhizomucor, D−1 (35), Neg, D6, D13 (>45) | D0 + isavuconazole (D8) | Death at D15 |
| 22 | 80 | M | AML | Possible IFD | Condensation, ground-glass opacity | Not done | D0, Neg, Neg | Neg | Mucor/Rhizopus, D0 (29) | Mucor/Rhizopus, D−5 (34), D−1 (32) | D6 | Death at D7 |
| 23 | 56 | M | AML, HSCT | Possible IFD | Reverse halo sign | Not done | D0, Neg, Neg | Neg | Rhizomucor, D0 (32) | Rhizomucor D0 (31) | D0 | Death at D2 |
| 24 | 66 | M | Sarcoidosis | No IFD | Not done | Not done | D0, Neg, Neg | Pos (BAL fluid 0.93) | Lichtheimia, D0 (41) | Neg, D0 (>45) | None | Death at D10 |
a
F, female; M, male.
b
NHL, non-Hodgkin's lymphoma; HSCT, allogeneic hematopoietic stem cell transplant; AML, acute myeloblastic leukemia; ALL, acute lymphoblastic leukemia; IM, idiopathic myelofibrosis; MDS, myelodysplastic syndrome; CML, chronic myeloblastic leukemia.
c
IFD, invasive fungal disease. The “proven fusariosis” case had positive hemoculture with Fusarium spp. at D45.
d
L-AMB, liposomal amphotericin B.